Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer

08:00 EDT 4 Apr 2019 | Drugs.com

THURSDAY, April 4, 2019 -- Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of Surgery. Mark...

Original Article: Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer

More From BioPortfolio on "Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer"